Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246 ↗

Phase 3 Completed 1463 enrolled H. Lundbeck A/S

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).

Timeline

Start: 2014-04-07
Primary completion: 2017-07-06
Completion: 2017-07-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Idalopirdine	Small molecule	60 mg	Oral

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Summary

Timeline

Drugs

Indications